The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 14, 2021

Filed:

Oct. 21, 2020
Applicant:

Immunomedics, Inc., Morris Plains, NJ (US);

Inventors:

David M. Goldenberg, Delray Beach, FL (US);

Serengulam V. Govindan, Springfield, NJ (US);

Assignee:

Immunomedics, Inc., Morris Plains, NJ (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 47/68 (2017.01); A61K 31/4745 (2006.01); A61K 39/395 (2006.01); A61K 31/7068 (2006.01); A61K 45/06 (2006.01); A61K 31/337 (2006.01); A61K 31/4184 (2006.01); A61K 31/4375 (2006.01); A61K 31/454 (2006.01); A61K 31/513 (2006.01); A61K 31/675 (2006.01); A61K 31/7088 (2006.01); A61K 31/713 (2006.01); C07K 16/28 (2006.01); C07K 16/30 (2006.01); A61K 41/00 (2020.01); A61K 51/10 (2006.01); A61N 5/10 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 47/6851 (2017.08); A61K 31/337 (2013.01); A61K 31/4184 (2013.01); A61K 31/4375 (2013.01); A61K 31/454 (2013.01); A61K 31/4745 (2013.01); A61K 31/513 (2013.01); A61K 31/675 (2013.01); A61K 31/7068 (2013.01); A61K 31/7088 (2013.01); A61K 31/713 (2013.01); A61K 39/39558 (2013.01); A61K 41/0038 (2013.01); A61K 45/06 (2013.01); A61K 47/6803 (2017.08); A61K 47/6855 (2017.08); A61K 47/6859 (2017.08); A61K 47/6863 (2017.08); A61K 47/6889 (2017.08); A61K 51/1045 (2013.01); C07K 16/2803 (2013.01); C07K 16/2833 (2013.01); C07K 16/2887 (2013.01); C07K 16/30 (2013.01); C07K 16/3007 (2013.01); C07K 16/3076 (2013.01); A61K 2039/505 (2013.01); A61N 5/1001 (2013.01); A61N 2005/1021 (2013.01); C07K 2317/24 (2013.01); C07K 2317/33 (2013.01); C07K 2317/732 (2013.01); C07K 2317/77 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01);
Abstract

The present invention relates to therapeutic immunoconjugates comprising SN-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to Trop-2 or CEACAM5 and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 16 mg/kg, preferably 4, 6, 8, 9, 10, 12, or 16 mg/kg. When administered at specified dosages and schedules, the immunoconjugate can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy. Surprisingly, the immunoconjugate is effective to treat cancers that are refractory to or relapsed from irinotecan.


Find Patent Forward Citations

Loading…